AEGLEA BIOTHERAPEUTICS INC.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Aeglea Biotherapeutics stock, expecting significant price increases ahead.
Financial Health
AEGLEA BIOTHERAPEUTICS INC. shows promising cash flow and solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage pipeline
Several programmes in clinical trials can act as potential catalysts, though outcomes are binary and unpredictable.
Novel enzyme approach
Engineered enzymes aim to address metabolic and oncology needs, offering scientific promise but with execution and regulatory hurdles.
Risk and outlook
Small-cap biotech exposure can offer growth potential but brings volatility, funding and liquidity risks—suitability depends on investor goals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
